StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Amgen (AMGN) wins FDA panel backing for biosimilar Humira in U.S. - Bloomberg
July 12, 2016 4:23 PM
Amgen (NASDAQ: AMGN) wins FDA ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Hot FDA News
Trader Talk
Next Articles
Jefferies Reiterates Buy on Amgen (AMGN) Following FDA Approval of Humira Biosimilar
July 13, 2016 8:24 AM
Amgen (AMGN) Announces Meeting with U.S. FDA to Discuss ABP 501 BLA
July 12, 2016 7:32 AM
Amgen To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate To Adalimumab
July 12, 2016 7:30 AM
Amgen's (AMGN) Repatha Pushtronex System Receives FDA Approval
July 11, 2016 9:03 AM
FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor
July 11, 2016 9:02 AM
